CC-99282

Phase 2Small molecule

Bristol-Myers Squibb

CC-99282 is one of 108 small molecule programs targeting Lymphoma, B-Cell. It is currently in Phase 2.

Indications

Total Trials

Active Trials

107

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lymphoma, B-CellActive, not recruiting

Non-Hodgkin LymphomaActive, not recruiting

B CellRecruiting

LymphomaActive, not recruiting

Follicular LymphomaRecruiting

Lymphoma, B-CellPhase 1

Active, not recruiting

Non-Hodgkin LymphomaPhase 2

Active, not recruiting

B CellPhase 2

Recruiting

LymphomaPhase 2

Active, not recruiting

Follicular LymphomaPhase 2

Recruiting

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

CC-99282

Bristol-Myers Squibb

Phase 2

1 2

Zofran

Novartis

Preclinical

2 3

Cabenuva

GSK

Preclinical

1 4

Norvir

AbbVie

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Systemic Therapy

1 10

R-CHOP

IIncyte Biosciences Japan GK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Follicular Lymphoma

NCT06108232

Q1 2028

Phase 1/2Active, not recruiting

Lymphoma

NCT03930953

Q4 2028

Phase 1Active, not recruiting

Lymphoma, B-Cell

NCT04884035

Q2 2030

Phase 2Recruiting

B Cell

NCT06835530

Clinical

Trials by Indication[1]

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma1 trial

A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04434196·16 enrolled

Relapsed/Refractory B-cell Malignancies1 trial

A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03310619·62 enrolled

Lymphoma1 trial

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03930953·438 enrolled

Follicular Lymphoma1 trial

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06108232·83 enrolled

B Cell1 trial

A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Recruiting·FFondazione Italiana Linfomi - ETS·Phase 2·NCT06835530·47 enrolled

2 more indications

Lymphoma, B-Cell1 trial

A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) in Combination With R-CHOP-21 and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated Aggressive B-cell Lymphoma

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04884035·224 enrolled

Non-Hodgkin Lymphoma1 trial

Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma

Active, not recruiting· Genmab logo

Genmab·Phase 2·NCT05283720·264 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for CC-99282. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CC-99282 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CC-99282. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Bristol-Myers Squibb

CC-99282

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2028

Q4 2028

Q2 2030

Trials by Indication[1]

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma1 trial

Relapsed/Refractory B-cell Malignancies1 trial

Lymphoma1 trial

Follicular Lymphoma1 trial

B Cell1 trial

Lymphoma, B-Cell1 trial

Non-Hodgkin Lymphoma1 trial

References

Drug Info

Quick Facts

Related News